Form 4: C4 Therapeutics Executive Kelly Schick Reports Stock Transactions

Kelly Schick, Chief People Officer at C4 Therapeutics, reports the vesting of performance restricted stock units and subsequent tax withholding.

Summary

• On November 7, 2024, Kelly Schick, Chief People Officer of C4 Therapeutics, engaged in transactions involving the company's common stock.
• 3,750 shares were acquired through the vesting of performance restricted stock units (PRSUs).
• 1,102 shares were withheld by C4 Therapeutics to cover tax obligations related to the PRSU vesting at a price of $6.04 per share.
• Following these transactions, Schick directly owns 56,488 shares of C4 Therapeutics common stock and 10,500 performance restricted stock units.
• The PRSUs vest upon the achievement of share price and clinical milestones, with 4,500 PRSUs tied to share price targets and the remainder linked to discovery and clinical goals.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't indicate any significant positive or negative sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.

Stakeholder Impact

• Shareholders can monitor insider transactions to assess management's confidence in the company.
• Employees may be interested in the vesting schedules and terms of executive compensation.

Key Dates